PharmaTher Granted FDA Orphan Drug Designation For Ketamine To Treat Amyotrophic Lateral Sclerosis

PharmaTher Holdings Ltd. announced that the FDA has granted orphan drug designation for ketamine in the treatment of Amyotrophic Lateral Sclerosis, also known as Lou Gehrig’s disease.